Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes

Archives of General Psychiatry

Volumn 69, Issue 7, 2012, Pages 706-714

  El Marroun, Hanan ^a,b   Jaddoe, Vincent W V ^b   Hudziak, James J ^a,c   Roza, Sabine J ^a,b   Steegers, Eric A P ^b   Hofman, Albert ^b   Verhulst, Frank C ^a   White, Tonya J H ^a,b   Stricker, Bruno H C ^b   Tiemeier, Henning ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY GROWTH; BRIEF SYMPTOM INVENTORY; CEPHALOMETRY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS GROWTH; FETUS WEIGHT; HEAD CIRCUMFERENCE; HIGH RISK PATIENT; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; QUESTIONNAIRE; SIDE EFFECT; SMALL FOR DATE INFANT;

ADULT; ANTIDEPRESSIVE AGENTS; CEPHALOMETRY; DEPRESSIVE DISORDER; FEMALE; FETAL DEVELOPMENT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PREGNANCY; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; ULTRASONOGRAPHY, PRENATAL;

EID: 84863556232     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.2333     Document Type: Article

References (63)

1. Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16 (5):560-570. (Pubitemid 46824278)
2. Ravera S, Visser ST, de Gier JJ, de Jong-van den Berg LT. Prevalence, cumulative incidence, monotherapy and combination therapy, and treatment duration of frequently prescribed psychoactive medications in the Netherlands: retrospective database analysis for the years 2000 to 2005. Clin Ther. 2010;32(14): 2457-2466.
3. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(suppl 15):42-48. (Pubitemid 28467477)
4. Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606. (Pubitemid 351365128)
5. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002-1012. (Pubitemid 37486676)
6. Mercado R, Floran B, Hernandez J. Regulated release of serotonin from axonal growth cones isolated from the fetal rat brain. Neurochem Int. 1998;32(1): 103-106. (Pubitemid 28020243)
7. Fillion MP, Hernandez RJ, Bauguen C, Fillion G. Postnatal development of high affinity neuronal recognition sites for 3H-5-HT in rat brain. Dev Neurosci. 1982; 5(5-6):484-491. (Pubitemid 13220977)
8. Nebigil CG, Etienne N, Schaerlinger B, Hickel P, Launay JM, Maroteaux L. Developmentally regulated serotonin 5-HT2B receptors. Int J Dev Neurosci. 2001; 19(4):365-372. (Pubitemid 32500332)
9. Rayburn WF, Gonzalez CL, Christensen HD, Kupiec TC, Jacobsen JA, Stewart JD. Effect of antenatal exposure to paroxetine (Paxil) on growth and physical maturation of mice offspring. J Matern Fetal Med. 2000;9(2):136-141. (Pubitemid 30368455)
10. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci. 2010;31(2):60-65.
11. Lee LJ. Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res. 2009;15(3):212-223.
12. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG. 2002;109(9):1003-1008. (Pubitemid 35279130)
13. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160(5):993-996. (Pubitemid 41079587)
14. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18(3):246-252.
15. Campagne DM. Fact: antidepressants and anxiolytics are not safe during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007;135(2):145-148. (Pubitemid 350186212)
16. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One. 2008;3(7):e2782.
17. Mulder EJ, Ververs FF, deHeus R, Visser GH. Selective serotonin reuptake inhibitors affect neurobehavioral development in thehumanfetus. Neuropsychopharmacology. 2011;36(10):1961-1971.
18. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125 (3):e600-e608.
19. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402-408. (Pubitemid 36521227)
20. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288-291. (Pubitemid 32299548)
21. Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr. 2010;15(3):167-185.
22. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726-735. (Pubitemid 40100521)
23. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162(1):79-91. (Pubitemid 40095676)
24. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009; 166(5):557-566.
25. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115(8):1043-1051. (Pubitemid 351841766)
26. Hay DF, Pawlby S, Waters CS, Sharp D. Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J Child Psychol Psychiatry. 2008;49(10):1079-1088.
27. Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child language development. J Child Psychol Psychiatry. 2009;50(3):254-262.
28. Jaddoe VW, van Duijn CM, van der Heijden AJ, Mackenbach JP, Moll HA, Steegers EA, Tiemeier H, Uitterlinden AG, Verhulst FC, Hofman A. The Generation R Study: design and cohort update 2010. Eur J Epidemiol. 2010;25(11):823-841.
29. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13(3):595-605.
30. de Beurs E. Brief Symptom Inventory, Handleiding. Leiden, the Netherlands: PITS; 2004.
31. Verburg BO, Steegers EA, De Ridder M, Snijders RJ, Smith E, Hofman A, Moll HA, Jaddoe VW, Witteman JC. New charts for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a population-based cohort study. Ultrasound Obstet Gynecol. 2008;31(4):388-396.
32. Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK. Sonographic estimation of fetal weight: the value of femur length in addition to head and abdomen measurements. Radiology. 1984;150(2):535-540. (Pubitemid 14179487)
33. Verburg BO, Mulder PG, Hofman A, Jaddoe VW, Witteman JC, Steegers EA. Intra- and interobserver reproducibility study of early fetal growth parameters. Prenat Diagn. 2008;28(4):323-331. (Pubitemid 351519071)
34. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137. (Pubitemid 19030705)
35. Migrants in the Netherlands 2004. Statistics Netherlands website. http://www.cbs.nl. Accessed November 18, 2010.
36. Standard classification of education 2003. Statistics Netherlands website. http: //www.cbs.nl. Accessed November 18, 2010.
37. Roza SJ, Verburg BO, Jaddoe VW, Hofman A, Mackenbach JP, Steegers EA, Witteman JC, Verhulst FC, Tiemeier H. Effects of maternal smoking in pregnancy on prenatal brain development: the Generation R Study. Eur J Neurosci. 2007;25(3):611-617.
38. El Marroun H, Tiemeier H, Jaddoe VW, Hofman A, Verhulst FC, van den Brink W, Huizink AC. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study. Eur Addict Res. 2011;17(1):37-43.
39. Twisk JWR. Applied Multilevel Analysis: A Practical Guide for Medical Researchers. Cambridge, England: Cambridge University Press; 2006.
40. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28(5):964-974. (Pubitemid 29525041)
41. Matthews JN, Altman DG. Interaction 3: how to examine heterogeneity. BMJ. 1996; 313(7061):862. (Pubitemid 26335214)
42. Matthews JN, Altman DG. Statistics notes, interaction 2: compare effect sizes not P values. BMJ. 1996;313(7060):808. (Pubitemid 26326887)
43. Young-Davies CL, Bennett-Clarke CA, Lane RD, Rhoades RW. Selective facilitation of the serotonin(1B) receptor causes disorganization of thalamic afferents and barrels in somatosensory cortex of rat. J Comp Neurol. 2000;425(1):130-138.
44. Xu Y, Sari Y, Zhou FC. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res. 2004;150(2):151-161. (Pubitemid 38639819)
45. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31(1):47-57. (Pubitemid 43250940)
46. Silva LM, Jansen PW, Steegers EA, Jaddoe VW, Arends LR, Tiemeier H, Verhulst FC, Moll HA, Hofman A, Mackenbach JP, Raat H. Mother's educational level and fetal growth: the genesis of health inequalities. Int J Epidemiol. 2010;39 (5):1250-1261.
47. Baschat AA. Fetal responses to placental insufficiency: an update. BJOG. 2004; 111(10):1031-1041. (Pubitemid 39319260)
48. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A metaanalysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10): 1012-1024.
49. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906. (Pubitemid 44188483)
50. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009; 163(10):949-954.
51. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055-2061. (Pubitemid 35423865)
52. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015. (Pubitemid 26338730)
53. El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, van den Brink W, Huizink AC. Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry. 2009; 48(12):1173-1181.
54. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand. 2011;123(4):266- 275.
55. Austin MP. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006;36(12):1663-1670.
56. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198 (2):194-195, e1-e5.
57. Cooke RW, Lucas A, Yudkin PL, Pryse-Davies J. Head circumference as an index of brain weight in the fetus and newborn. Early Hum Dev. 1977;1(2):145-149. (Pubitemid 8224192)
58. Epstein HT, Epstein EB. The relationship between brain weight and head circumference from birth to age 18 years. Am J Phys Anthropol. 1978;48(4):471- 473.
59. Herba CM, Roza SJ, Govaert P, van Rossum J, Hofman A, Jaddoe V, Verhulst FC, Tiemeier H. Infant brain development and vulnerability to later internalizing difficulties: the Generation R study. J Am Acad Child Adolesc Psychiatry. 2010; 49(10):1053-1063.
60. Whitaker AH, Van Rossem R, Feldman JF, Schonfeld IS, Pinto-Martin JA, Tore C, Shaffer D, Paneth N. Psychiatric outcomes in low-birth-weight children at age 6 years: relation to neonatal cranial ultrasound abnormalities. Arch Gen Psychiatry. 1997;54(9):847-856. (Pubitemid 27383312)
61. Peterson BS, Anderson AW, Ehrenkranz R, Staib LH, Tageldin M, Colson E, Gore JC, Duncan CC, Makuch R, Ment LR. Regional brain volumes and their later neurodevelopmental correlates in term and preterm infants. Pediatrics. 2003;111 (5, pt 1):939-948. (Pubitemid 36542604)
62. Peterson BS, Vohr B, Staib LH, Cannistraci CJ, Dolberg A, Schneider KC, Katz KH, Westerveld M, Sparrow S, Anderson AW, Duncan CC, Makuch RW, Gore JC, Ment LR. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. JAMA. 2000;284(15):1939-1947.
63. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104-1112.